RU2742485C2 - Гетероциклическое соединение, используемое как ингибитор fgfr - Google Patents

Гетероциклическое соединение, используемое как ингибитор fgfr Download PDF

Info

Publication number
RU2742485C2
RU2742485C2 RU2019100164A RU2019100164A RU2742485C2 RU 2742485 C2 RU2742485 C2 RU 2742485C2 RU 2019100164 A RU2019100164 A RU 2019100164A RU 2019100164 A RU2019100164 A RU 2019100164A RU 2742485 C2 RU2742485 C2 RU 2742485C2
Authority
RU
Russia
Prior art keywords
pyrid
group
methyl
alkyl
compound
Prior art date
Application number
RU2019100164A
Other languages
English (en)
Russian (ru)
Other versions
RU2019100164A3 (enExample
RU2019100164A (ru
Inventor
Норман Сянлон КУН
Чао Чжоу
Жисян ЧЖЭН
Original Assignee
Нанцзин Иннокэар Фарма Тек Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нанцзин Иннокэар Фарма Тек Ко., Лтд. filed Critical Нанцзин Иннокэар Фарма Тек Ко., Лтд.
Publication of RU2019100164A publication Critical patent/RU2019100164A/ru
Publication of RU2019100164A3 publication Critical patent/RU2019100164A3/ru
Application granted granted Critical
Publication of RU2742485C2 publication Critical patent/RU2742485C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2019100164A 2016-07-13 2017-06-13 Гетероциклическое соединение, используемое как ингибитор fgfr RU2742485C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610550151.3 2016-07-13
CN201610550151.3A CN107619388A (zh) 2016-07-13 2016-07-13 作为fgfr抑制剂的杂环化合物
PCT/CN2017/088038 WO2018010514A1 (zh) 2016-07-13 2017-06-13 作为fgfr抑制剂的杂环化合物

Publications (3)

Publication Number Publication Date
RU2019100164A RU2019100164A (ru) 2020-08-13
RU2019100164A3 RU2019100164A3 (enExample) 2020-08-27
RU2742485C2 true RU2742485C2 (ru) 2021-02-08

Family

ID=60951887

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019100164A RU2742485C2 (ru) 2016-07-13 2017-06-13 Гетероциклическое соединение, используемое как ингибитор fgfr

Country Status (12)

Country Link
US (1) US10590109B2 (enExample)
EP (1) EP3489223A4 (enExample)
JP (1) JP6896852B2 (enExample)
KR (1) KR102386428B1 (enExample)
CN (2) CN107619388A (enExample)
AU (1) AU2017295628B2 (enExample)
CA (1) CA3030070A1 (enExample)
MX (1) MX386089B (enExample)
PH (1) PH12019500036A1 (enExample)
RU (1) RU2742485C2 (enExample)
SG (2) SG10202013038VA (enExample)
WO (1) WO2018010514A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2974003T3 (es) * 2017-08-04 2024-06-25 Abbisko Therapeutics Co Ltd Derivado de la formilpiridina con actividad inhibidora del FGFR4, método de preparación y uso del mismo
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
CN108129471A (zh) * 2018-03-20 2018-06-08 韩邦森 一种噻唑取代嘧啶类化合物的合成工艺
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN111039874B (zh) * 2019-12-13 2022-11-04 南开大学 一种2-胺基-4-甲基嘧啶化合物的零废水制备方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1508130A (zh) * 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
WO2006000420A1 (en) * 2004-06-24 2006-01-05 Novartis Ag Pyrimidine urea derivatives as kinase inhibitors
WO2006009741A1 (en) * 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
WO2007017577A1 (fr) * 2005-08-04 2007-02-15 Aventis Pharma S.A. 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007059341A2 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
WO2008065282A2 (fr) * 2006-11-10 2008-06-05 Sanofi-Aventis Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
RU2340605C2 (ru) * 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
CN102471280A (zh) * 2009-07-03 2012-05-23 赛诺菲 吡唑衍生物、其制备及其治疗用途
WO2013024427A1 (en) * 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1790342A1 (de) * 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
KR101461680B1 (ko) * 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
BR112016008276B1 (pt) * 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
CA2976766A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Formylated n-heterocyclic derivatives as fgfr4 inhibitors

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2340605C2 (ru) * 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
CN1508130A (zh) * 2002-12-18 2004-06-30 中国科学院大连化学物理研究所 N-苯基-n’-嘧啶基取代脲类衍生物的合成方法
WO2006009741A1 (en) * 2004-06-23 2006-01-26 Eli Lilly And Company Kinase inhibitors
WO2006000420A1 (en) * 2004-06-24 2006-01-05 Novartis Ag Pyrimidine urea derivatives as kinase inhibitors
WO2007017577A1 (fr) * 2005-08-04 2007-02-15 Aventis Pharma S.A. 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007059341A2 (en) * 2005-11-16 2007-05-24 Sgx Pharmaceuticals, Inc. Pyrazolothiazole protein kinase modulators
WO2007059341A3 (en) * 2005-11-16 2007-11-29 Sgx Pharmaceuticals Inc Pyrazolothiazole protein kinase modulators
WO2008065282A2 (fr) * 2006-11-10 2008-06-05 Sanofi-Aventis Pyrazoles substituees, compositions les contenant, procede de fabrication et utilisation
CN102471280A (zh) * 2009-07-03 2012-05-23 赛诺菲 吡唑衍生物、其制备及其治疗用途
WO2013024427A1 (en) * 2011-08-16 2013-02-21 Glenmark Pharmaceuticals S.A. Novel urea derivatives as tec kinase inhibitors and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Gaoquan Li et al. "Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors", Bioorganic & Medicinal Chemistry Letters 16 (2006) 2293-2298. *
Gaoquan Li et al. "Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors", Bioorganic & Medicinal Chemistry Letters 16 (2006) 2293-2298. Kentaro Nagamatsu "Reactions of 2-Triphenylphosphoimino-1-azaazulenes with Aryl Isocyanates and Aryl Isothiocyanates", Heterocycles, Vol 67, No. 1, 2006, pp.337-351. Jonathan Clayden et al "N,N′-Diarylureas: A New Family of Atropisomers Exhibiting Highly Diastereoselective Reactivity", J. Org. Chem. Vol. 73, No. 12, 2008, pp. 44-15-4423. Ki-Hyun Kim et al. "Conformational Switching on Platinum(II) Coordination Plane Triggered by Oxalate Anion", Bulletin of the Korean Chemical Society 2011, Vol. 32, No. 9, pp. 3497-3500. Tsan-Wen Lu et al. "Molecular Switch Based on Very Weak Association between BPX26C6 and Two Recognition Units", ORGANIC LETTERS, 2013, Vol. 15, No. 22, 5742-5745 . Zhao Yang et al. "Identification of inhibitors for vascular endothelial growth factor receptor *
Jonathan Clayden et al "N,N′-Diarylureas: A New Family of Atropisomers Exhibiting Highly Diastereoselective Reactivity", J. Org. Chem. Vol. 73, No. 12, 2008, pp. 44-15-4423. *
Kentaro Nagamatsu "Reactions of 2-Triphenylphosphoimino-1-azaazulenes with Aryl Isocyanates and Aryl Isothiocyanates", Heterocycles, Vol 67, No. 1, 2006, pp.337-351. *
Tsan-Wen Lu et al. "Molecular Switch Based on Very Weak Association between BPX26C6 and Two Recognition Units", ORGANIC LETTERS, 2013, Vol. 15, No. 22, 5742-5745 . *
Ying An et al. "Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors", Bioorganic & Medicinal Chemistry Letters, Volume 26, Issue 13, 2016, pp. 3067-3072. *
Zhao Yang et al. "Identification of inhibitors for vascular endothelial growth factor receptor by using dynamic combinatorial chemistry", Bioorganic & Medicinal Chemistry Letters, Volume 26, Issue 7, 2016, рр. 1671-1674. *

Also Published As

Publication number Publication date
MX2019000451A (es) 2019-09-27
WO2018010514A1 (zh) 2018-01-18
KR102386428B1 (ko) 2022-04-14
CN108349896A (zh) 2018-07-31
AU2017295628A1 (en) 2019-02-21
RU2019100164A3 (enExample) 2020-08-27
AU2017295628B2 (en) 2021-05-13
US20190144427A1 (en) 2019-05-16
KR20190032420A (ko) 2019-03-27
CA3030070A1 (en) 2018-01-18
SG11201900298RA (en) 2019-02-27
PH12019500036A1 (en) 2019-10-28
SG10202013038VA (en) 2021-01-28
CN107619388A (zh) 2018-01-23
EP3489223A1 (en) 2019-05-29
US10590109B2 (en) 2020-03-17
CN108349896B (zh) 2021-06-01
JP2019522055A (ja) 2019-08-08
JP6896852B2 (ja) 2021-06-30
EP3489223A4 (en) 2020-01-15
MX386089B (es) 2025-03-18
RU2019100164A (ru) 2020-08-13

Similar Documents

Publication Publication Date Title
JP6896852B2 (ja) Ｆｇｆｒ阻害剤として使用される複素環式化合物
JP7716110B2 (ja) ピリミジン－４（３ｈ）－オンヘテロ環式化合物、その調製方法、およびその医薬的使用
JP6959663B2 (ja) Ｆｇｆｒ阻害剤としての複素環化合物
TWI765908B (zh) 苯並咪唑類化合物激酶抑制劑及其製備方法和應用
RU2747260C2 (ru) Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CN109020957B (zh) 作为mnk抑制剂的杂环化合物
IL277518B2 (en) Substituted imidazolidin-2-one derivatives as prmt5 inhibitors
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
AU2017327954A1 (en) Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof
BR112014029851B1 (pt) Composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, agente para tratamento de um tumor, e uso do referido composto
JP2023518609A (ja) 新規アミノピリミジン系ｅｇｆｒ阻害剤
CN105884695B (zh) 杂环衍生物类酪氨酸激酶抑制剂
KR20210145773A (ko) 티에노헤테로고리형 유도체, 이의 제조 방법 및 이의 의약적 용도
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
KR20250154490A (ko) 방향족 아미드 유도체, 이의 제조 방법, 및 그의 용도
WO2020200154A1 (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
RU2839367C1 (ru) Гетероциклическое соединение пиримидин-4(3h)-она, способ его получения и его фармацевтическое применение
HK1245261A1 (zh) 作为fgfr抑制剂的杂环化合物
HK40072883A (en) Pyrimidine-4(3h)-ketone heterocyclic compound, preparation method therefor and use thereof in medicine and pharmacology
CN120943837A (zh) 作为酪氨酸激酶抑制剂的杂环化合物
KR20230142000A (ko) 아이소옥사졸리딘 유도체 화합물 및 이의 용도
HK1258833A1 (zh) 作为fgfr抑制剂的杂环化合物
HK1258833B (zh) 作为fgfr抑制剂的杂环化合物
TW201305171A (zh) 酞嗪酮類衍生物、其製備方法及其在醫藥上的應用